The Effectiveness of ACB-IP 1.0 Convalescent Plasma in COVID-19 Infection

The Effectiveness of ACB-IP 1.0 Universal Pathogen Free Concentrated Cocktail Convalescent Plasma in COVID-19 Infection

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04769245

Enrollment

Registered

2021-02-24

Start date

2021-02-18

Completion date

2021-06-01

Last updated

2021-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Brief summary

Pathogen-free, concentrated, pooled convalescent plasma has higher SARS-CoV2 antibody titers and neutralizing antibody activities, without requiring blood group compatibility that allows patient accessibility in a shorter time and has safe plasma characteristic.

Detailed description

The efficacy of SARS-CoV2 standard single donor convalescent plasma varied according to the application time and most importantly the amount of antibody that is administered. Single donor plasma has some drawbacks; such as the insufficient levels of neutralizing antibody activities, the requirements of blood group compatibility, and the risk of infection transmission. In this study, the efficacy and safety of pathogen inactivated, isohemagglutinin-depleted (concentrated) and pooled convalescent plasma was investigated.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Inclusion criteria

* Are over the age of 60 or- * Between the ages of 18-60, serious comorbidities (cancer, COPD, cardiovascular illness, hypertension, DM) * Clinically diagnose COVID-19 or radiological diagnosed COVID-19 pnemonia

Exclusion criteria

* Multiple Organ Failure

Design outcomes

Primary

Measure	Time frame	Description
Mortality Rate	6 Months	A mortality rate is a measure of the frequency of occurrence of death in a defined population during a specified interval.
Length of Hospitalization	6 Months	The average length of stay in hospitals (ALOS) is often used as an indicator of efficiency

Secondary

Measure	Time frame	Description
Side Effects	6 Months	Problems that occur when treatment goes beyond the desired effect. Or problems that occur in addition to the desired therapeutic effect.

Countries

Turkey (Türkiye)

Contacts

Primary ContactErcument Ovalı, MD

ercument.ovali@acibadem.com+905325729174

Backup ContactCansu Hemsinlioglu

chemsinlioglu@gmail.com+905356782771

Outcome results